Markets

Bristol-Myers/Neon Therapeutics Ink Immuno-Oncology Deal

Outdoor LED panel of a stock graph

Bristol-Myers Squibb CompanyBMY entered into an agreement with an immuno-oncology company, Neon Therapeutics. As per the terms on the collaboration, the companies will evaluate the combination of Neon Therapeutics' proprietary personalized neoantigen vaccine, NEO-PV-01, and Bristol-Myers programmed death receptor-1 (PD-1) immune checkpoint inhibitor, Opdivo.

The companies plan to conduct a phase Ib study to evaluate the safety, tolerability and preliminary efficacy of NEO-PV-01 in patients receiving Opdivo in melanoma, smoking-associated non-small cell lung cancer, and bladder cancer. The study will also evaluate neoantigen-specific immune responses in peripheral blood and tumor tissue, as well as other indicators of immune response such as PD-L1 expression. The study is expected to be initiated in 2016.

Apart from this, Bristol-Myers has been aggressively inking deals with other health care companies like Eli Lilly and Company LLY to study its high-profile immuno-oncology drug Opdivo to be used either alone or in combination with other therapies in multiple tumor types. The drug generated revenues of $305 million in the third quarter of 2015 compared with $122 million in the previous quarter. Bristol-Myers continues to work on label expansion of the drug to boost sales.

As licensing agreements and acquisitions in the highly lucrative immuno-oncology space continue to attract attention, we expect to see more of such deals over the coming months.

Bristol-Myers currently carries a Zacks Rank #2 (Buy). A couple of other well-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN and Corcept Therapeutics Incorporated CORT , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CORT LLY BMY

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More